AMGN241018P345000
- 16.80
- 0.000.00%
Amgen Newsroom
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Amgen Seeing Muted Upside Potential for Drug Pipeline, Truist Says
Amgen's stock price has dropped, analysts warn that the speculation on weight loss drugs has already been digested by the market.
Amgen Inc.'s stocks fell on Monday as an analyst no longer holds a positive view on this biotechnology giant. The concern is that investors' optimism about the candidate obesity drug has already been priced into the stock, with more downside risks than upside opportunities. Truist analyst Srikripa Devarakonda downgraded the stock from a buy rating for the past 11 months to a hold. However, she raised the target price from $320 to $333, but the new target price is only 1.4% higher than last Friday's closing price. The stock declined 1.1% in pre-market trading on Monday, following last Friday's gain.
Amgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.
Amgen Analyst Ratings
Amgen Inc. (NASDAQ:AMGN) Delivered A Better ROE Than Its Industry
Amgen Downgraded at Truist on MariTide Prospects for Obesity
Truist Financial Downgrades Amgen(AMGN.US) to Hold Rating, Announces Target Price $333
JPMorgan Chase, Goldman Sachs Share Gains Lead Dow's 430-Point Rally
Morgan Stanley Adjusts Price Target on Amgen to $319 From $316
Morgan Stanley Keeps Their Hold Rating on Amgen (AMGN)
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
High Dividend Growth + High Free Cash Flow Yield Stocks = a Winning Strategy
Amgen Inc. (NASDAQ:AMGN) Is Largely Controlled by Institutional Shareholders Who Own 78% of the Company
Goldman Sees a 'Relief Rally' Potential for These Option Calls Ahead of Earnings
Deere, Amgen, Copart And More: CNBC's 'Final Trades'
Healthcare Stocks Are Showing Life Beyond Lilly and GLP-1s -- Barrons.com
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Unusual Options Activity: EXPE, ALAB and Others Attract Market Bets, EXPE V/OI Ratio Reaches 95.2
EST Oct 9th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options